Urinalysis Market Projected to Reach $7.16 Billion by 2031, Driven by Automation and Point-of-Care Adoption
核心洞察
The global urinalysis market is projected to grow from USD 4.88 billion in 2026 to USD 7.16 billion by 2031, at a compound annual growth rate (CAGR) of 8.0%.
The consumables segment held the largest market share at 72.5% in 2025, while pregnancy and fertility tests led test types with a 42.8% share.
North America remains the largest regional market, with Asia Pacific expected to register the fastest growth during the forecast period.
The global urinalysis market is on track to expand from USD 4.88 billion in 2026 to USD 7.16 billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.0% over the forecast period, according to a new report from MarketsandMarkets. The growth trajectory underscores the increasing clinical reliance on urine-based diagnostics across hospitals, diagnostic laboratories, and home care settings, driven by the rising burden of chronic and infectious conditions and a broader shift toward automation.
Market Drivers and Clinical Demand
Several converging factors are fueling demand for urinalysis testing. The report highlights the rising prevalence of urinary tract infections (搜索) (UTIs), diabetes (搜索), and kidney and liver diseases (搜索), as well as a growing geriatric population and associated age-related disorders. These trends are intensifying the need for early disease detection, routine health screening, and disease monitoring. Additionally, the increasing adoption of point-of-care (PoC) testing and rising healthcare expenditure—particularly in emerging markets—are driving demand for advanced urinalysis analyzers, test strips, reagents, and other diagnostic products.
Technological advancements, including automated urine analyzers, digital microscopy, flow cytometry, and advanced biochemical testing, have significantly improved the speed, accuracy, and efficiency of urinalysis. A major development transforming the market is the growing adoption of automated and integrated urine analysis systems, which streamline sample processing, reduce manual intervention, improve workflow management, and enable rapid urine analysis. Automation minimizes operator-related errors, enhances testing consistency, and increases laboratory throughput, making these technologies well suited for high-volume healthcare settings.
Product and Test Type Segmentation
By product, the urinalysis market is segmented into consumables and instruments. The consumables segment held the largest market share in 2025, accounting for 72.5% of the market, driven by their recurring use and frequent replacement needs. Products such as pregnancy and fertility kits, dipsticks, reagents, and disposables generate continuous demand across hospitals, diagnostic laboratories, clinics, and home care settings.
By test type, the market is segmented into biochemical tests, sediment urinalysis, and pregnancy and fertility tests. The pregnancy and fertility tests segment accounted for the largest market share of 42.8% in 2025, supported by growing awareness of reproductive health and family planning, particularly in developing countries. Technological advancements have improved the accuracy, ease of use, and speed of these tests, while convenient home-based testing and rapid results have further increased adoption.
Regional Landscape
The urinalysis market is segmented into five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2025, North America accounted for the largest share of the market, supported by well-established healthcare infrastructure, advanced diagnostic facilities, and a skilled healthcare workforce. The region's high adoption of automated urine analyzers and the high prevalence of chronic conditions such as diabetes (搜索), kidney diseases (搜索), and urinary tract infections (搜索) contribute to its leading position.
Asia Pacific is expected to register the fastest growth in the urinalysis market during the forecast period, reflecting rising healthcare expenditure and expanding diagnostic testing volumes in emerging markets.
Competitive Landscape and Recent Developments
The top five players in the global urinalysis market accounted for approximately 52.0% of total market revenue in 2025, indicating a moderately consolidated competitive landscape. Siemens Healthineers AG (搜索) and F. Hoffmann-La Roche Ltd. dominate the market, supported by broad product portfolios, established global presence, and strong distribution networks. The top 10 companies collectively accounted for approximately 72–78% of global market revenue, including Cardinal Health, Sysmex Corporation, Thermo Fisher Scientific, Inc. (搜索), Danaher Corporation (搜索), Abbott (搜索), Bio-Rad Laboratories, Inc., QuidelOrtho Corporation (搜索), and Waters Corporation (搜索).
The market has seen sustained strategic investment and product launches. Siemens Healthineers AG (搜索) launched the Atellica UAS 60 Analyzer in December 2023, a compact instrument for automated urine sediment analysis offering a space-efficient, high-throughput solution. More recently, Danaher Corporation (搜索) launched the DxU 1800 System in July 2026, a fully automated urinalysis solution combining a new urine chemistry analyzer and consumables with microscopy technology, designed to standardize urine testing, increase throughput, and reduce manual intervention.
Mergers and acquisitions in the urinalysis market are increasingly focused on expanding capabilities in automated urine testing, rapid diagnostics, digital microscopy, biochemical analysis, and integrated urinalysis workflows, as companies pursue acquisitions and strategic partnerships to broaden product portfolios and strengthen their presence across clinical laboratories, hospitals, and point-of-care settings.